专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US10961319B2 Anti-transglutaminase 2 antibodies 有权
公开(公告)号：US10961319B2
公开(公告)日：2021-03-30
申请号：US15987611
申请日：2018-05-23
申请人： LIFEARC
发明人： Tim Johnson , Phil Watson , David Matthews , Alex Brown
IPC分类号： C07K16/40 , A61K51/10 , A61K39/00
摘要： The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (TG2). Novel epitopes within the TG2 core are provided. The invention provides human TG2 inhibitory antibodies and uses thereof, particularly in medicine, for example in the treatment and/or diagnosis of conditions including Celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurological diseases and cancer.

22. 发明申请

US20210052692A1 A COMPOSITION FOR TREATING ONE OR MORE ESTROGEN RELATED DISEASES 有权
公开(公告)号：US20210052692A1
公开(公告)日：2021-02-25
申请号：US17050430
申请日：2019-04-25
申请人： LIFEARC
发明人： Finn LARSEN , Carol Marion MACLEAN
IPC分类号： A61K38/09 , A61P5/32
摘要： The present invention relates to treating one or more estrogen related diseases while preventing or reducing the likelihood of developing estrogen deficiency related side effects, wherein said composition comprises administering a therapeutically effective amount of a Gn RH antagonist to a patient in need of said treatment, and wherein said amount of Gn RH antagonist is sufficient for providing a mean endogenous serum estradiol level of between about 20 pg/ml and 60 pg/ml, preferably between 30 pg/ml and 50 pg/m, in said patient in a treatment period of at least four weeks, without relying on “add-back” therapy. Said composition and method is simple, effective and will accordingly both increase patient acceptance and compliance of therapy.

23. 发明授权

US10918645B2 Substituted tricyclic heterocyclic compounds and use thereof 有权
公开(公告)号：US10918645B2
公开(公告)日：2021-02-16
申请号：US16309227
申请日：2017-06-13
申请人： LIFEARC , SUZHOU YABAO PHARMACEUTICAL R&D CO., LTD.
发明人： Yan Xia , Edward Giles McIver , Yang Song , Yuanyuan Xu , Lin Zhu , Chunjun Chu , Ling Wu , Miao Liu , Justin Stephen Bryans
IPC分类号： C07D471/14 , C07D471/22 , C07D487/16 , A61K31/55 , A61P25/00 , A61P35/00
摘要： Provided are a substituted tricyclic heterocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical composition including the same and uses thereof. The substituted tricyclic heterocyclic compounds and the pharmaceutical compositions comprising the compounds disclosed herein can be used for treating a disorder caused by at least one of cancer and neurodegenerative diseases. Further the compounds and the pharmaceutical compositions comprising the compounds disclosed herein can be also used for preventing or treating a disorder caused by, associated with or accompanied by any abnormal kinase activity.

24. 发明授权

US10604524B2 Pyrropyrimidine compounds as MNKs inhibitors 有权
公开(公告)号：US10604524B2
公开(公告)日：2020-03-31
申请号：US15776574
申请日：2016-11-16
申请人： LIFEARC
发明人： Jon James Winter-Holt , Edward Giles Mciver , Stephen Lewis , Joanne Osborne
IPC分类号： C07D487/04 , A61K31/519 , A61K45/06
摘要： The present invention relates to compounds of formulae I, or pharmaceutically acceptable salts or esters thereof, wherein: R1 is selected from H and CO—NR8R9, wherein R8 and R9 are each independently selected from H, alkyl, cycloalkyl and mono or bicyclic heterocycloalkyl, wherein said alkyl group is optionally substituted by one or more R12 groups, and said heterocycloalkyl is optionally substituted by R10 or R12; or R8 and R9 are linked, together with the nitrogen to which they are attached, to form a heterocycloalkyl group optionally containing one or more additional heteroatoms, and optionally substituted by one or more groups select from R10 and (CH2)mR12; R2 is selected from H and alkyl, wherein said alkyl group is optionally substituted by one or more R12 groups; R3 is selected from alkyl, cycloalkyl and heterocycloalkyl, each of which may be optionally substituted by halo, OH or alkoxy; Z1, Z2, Z3 and Z4 are all C; R4, R5, R6 and R7 are each independently selected from H, alkyl, CN, NO2, OH, alkoxy, NHCO-alkyl, halo and haloalkyl; or Z1, Z3 and Z4 are all C, Z2 is N, R5 is absent and R4, R6 and R7 are as defined above; or Z1, Z3 and Z4 are all C, Z1 is N, R4 is absent and R5, R6 and R7 are as defined above; each R10 and R11 is independently alkyl; each R12 is independently selected from CO2R10, COOH, OH, alkoxy, haloalkyl, NH2, NHR10, NR10R11, heteroaryl and heterocycloalkyl; R13 is H or halo. Further aspects relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease.

25. 发明申请

US20190352295A1 OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER 审中-公开
公开(公告)号：US20190352295A1
公开(公告)日：2019-11-21
申请号：US16474114
申请日：2017-12-19
申请人： LIFEARC
发明人： Simon OSBORNE , Jonathan LARGE
IPC分类号： C07D413/14 , C07D413/12
摘要： A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, • B is a saturated or partially unsaturated monocyclic or bicyclic, heterocyclic group optionally substituted by one or more R 10 groups; * X is selected from SO2, CO2, CO, CONR11 and (CR12 R13) p. Said compounds are capable of inhibiting PAICS and are useful in the treatment of proliferative disorders. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formula (I).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式